Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.

Pharmaceutical

Sparrow Pharmaceuticals

Robert Jacks

Sarah H.

Jamie MacPherson

Jeff Drajesk

Frank Czerwiec

David Katz

Sparrow Pharmaceuticals' Leadership Team includes Robert Jacks and 4 others.

Leadership Team

About

Team members